---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-027554"
form_type: "8-K"
ticker: null
cik: "0000316253"
company_name: "ENZO BIOCHEM INC"
filed_at: "2023-04-05T23:59:59+00:00"
generated_at: "2026-06-17T06:06:14.910393+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Enzo Biochem enters $8M credit facility, borrows $5.5M; facility tied to clinical labs sale

## Summary
- $8M revolving credit facility with Gemino Healthcare Finance (SLR Healthcare ABL).
- Borrowed $5.5M at closing; proceeds for working capital and general corporate purposes.
- Interest rate: Term SOFR + 5.50% per annum; secured by substantially all U.S. assets.
- Facility expires March 29, 2024; will be prepaid upon closing of clinical labs asset sale.
- Minimum liquidity covenant: $4M (Apr 2023), $3M (May 2023), $2M thereafter.

## SEC filing metadata
- accession: 0001213900-23-027554
- form_type: 8-K
- cik: 0000316253
- company_name: ENZO BIOCHEM INC
- filed_at: 2023-04-05T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/316253/000121390023027554/0001213900-23-027554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/316253/000121390023027554/ea176546-8k_enzobio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-027554
- JSON: https://secwatch.observer/filing/0001213900-23-027554.json
- Plain text: https://secwatch.observer/filing/0001213900-23-027554.txt

## Key facts
- Debt Financings
  ENZO BIOCHEM INC incurred revolving credit of $8 million revolving line of credit; borrowed $5.5 million upon closing with Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL at Term SOFR for a three-month tenor plus 5.50% maturing after one year.
  - Instrument: revolving credit
  - Principal: $8 million revolving line of credit; borrowed $5.5 million upon closing
  - Counterparty: Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL
  - Rate: Term SOFR for a three-month tenor plus 5.50%
  - Maturity: after one year
  - Event: incurrence
  source text: of its domestic subsidiaries, as guarantors (the “Guarantors”), and Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL as lender. The Credit Facility provides for a maximum $8 million revolving line of credit. The Borrowers intend to use the borrowing proceeds under the Credit Facility for working capital and general corporate purposes. The commitment under
  evidence_url: https://www.sec.gov/Archives/edgar/data/316253/000121390023027554/0001213900-23-027554-index.htm
- Material Agreements
  ENZO BIOCHEM INC entered into Revolving Loan and Security Agreement with Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL valued at maximum $8 million revolving line of credit (effective 2023-03-31).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL
  - Value: maximum $8 million revolving line of credit
  - Effective: 2023-03-31
  source text: On March 31, 2023, Enzo Biochem, Inc. (the “Company”) entered into a Revolving Loan and Security Agreement (the “Credit Facility”) among Enzo Clinical Labs, Inc. and Enzo Life Sciences, Inc., as borrowers (the “Borrowers”), the Company and certain of its domestic subsidiaries, as guarantors (the “Guarantors”), and Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL as lender.
  evidence_url: https://www.sec.gov/Archives/edgar/data/316253/000121390023027554/0001213900-23-027554-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.